2.48
Schlusskurs vom Vortag:
$2.36
Offen:
$2.35
24-Stunden-Volumen:
780.46K
Relative Volume:
0.17
Marktkapitalisierung:
$425.37M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-124.00
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
+12.22%
1M Leistung:
-1.20%
6M Leistung:
+133.96%
1J Leistung:
+87.88%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
2.48 | 425.37M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
2021-11-15 | Eingeleitet | BTIG Research | Buy |
2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
2021-03-29 | Eingeleitet | JP Morgan | Overweight |
2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
2020-03-04 | Eingeleitet | Barclays | Equal Weight |
2019-11-20 | Eingeleitet | Guggenheim | Buy |
2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
2019-06-13 | Eingeleitet | Mizuho | Buy |
2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-03-11 | Eingeleitet | Barclays | Overweight |
2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
2018-10-15 | Eingeleitet | Goldman | Neutral |
2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
2018-06-01 | Eingeleitet | SunTrust | Buy |
2018-01-05 | Eingeleitet | Citigroup | Buy |
2017-09-08 | Eingeleitet | Wedbush | Outperform |
2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
2017-03-02 | Eingeleitet | Instinet | Buy |
2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
CytomX Therapeutics CEO Sells Shares to Meet Tax Obligations - TradingView
CytomX Therapeutics Approves Key Amendments at Annual Meeting - TipRanks
Stocks in play: Roots Corp. - The Globe and Mail
Two Sigma Investments LP Cuts Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail
GoldMining Announces Closing of Flow-Through Financing and Commences Exploration at Yellowknife Gold Project - The Globe and Mail
Ballard announces 1.5 MW fuel cell engine order for Sierra Northern Railway - The Globe and Mail
Northern Trust Corp Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
BMO Lowers Fees on Asset Allocation ETFs to Deliver Greater Value to Investors - The Globe and Mail
Millennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX stock soars to 52-week high, hits $2.66 By Investing.com - Investing.com South Africa
CytomX stock soars to 52-week high, hits $2.66 - Investing.com Australia
CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - The Manila Times
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus
CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com South Africa
CytomX begins trial of new melanoma treatment with Merck therapy - Investing.com Australia
CytomX (CTMX) Advances Phase 1 Study with CX-801 for Metastatic Melanoma | CTMX Stock News - GuruFocus
CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma - Nasdaq
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - The Manila Times
Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan
Equities Analysts Set Expectations for CTMX Q2 Earnings - Defense World
What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World
CytomX upgraded at H.C. Wainwright on trial data for cancer drug - MSN
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by HC Wainwright - Defense World
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
H.C. Wainwright raises CytomX stock to buy, target to $5.00 By Investing.com - Investing.com South Africa
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler - GuruFocus
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus
After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals
CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha
HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX - GuruFocus
H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus
HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5 - marketscreener.com
CytomX Therapeutics (CTMX) Price Target Doubled Following Promis - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX St - GuruFocus
CytomX Therapeutics (CTMX) Price Target Doubled Following Promising Trial Results | CTMX Stock News - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - MSN
Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st
CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets
CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks
CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha
CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):